BC28 CAR-T

BC28 CAR-T is an experimental second-generation chimeric antigen receptor (CAR) T-cell therapy designed to target B-cell maturation antigen (BCMA) for the treatment of multiple myeloma. Developed by researchers at the Technical University of Munich using the Bindcraft protein design pipeline, BC28 utilizes a computationally designed de novo binder (DNB) as its antigen-binding domain rather than a traditional antibody-derived fragment. This approach allows for the targeting of specific epitopes to overcome antigen escape mechanisms. In preclinical studies, BC28 CAR-T demonstrated robust cytotoxicity and cytokine production, showing comparable efficacy to clinical-stage BCMA CAR-T benchmarks. Notably, BC28 CAR-T maintains effectiveness against tumor cells harboring BCMA mutations that confer resistance to other therapies, such as the bispecific antibody teclistamab.